DSC2 Knockout MES-OV Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the DSC2 gene is disrupted in the MES-OV human ovarian cancer cell line. This polyclonal pool provides a heterogeneous loss-of-function model that mirrors the variability inherent in tumor cell populations, avoiding the artifacts of clonal selection. The CRISPR-mediated gene disruption targets the desmocollin-2 locus, enabling researchers to investigate the functional consequences of DSC2 ablation in a therapeutically relevant cellular context.
The host MES-OV line is an epithelial ovarian cancer cell model with a predominantly mesenchymal molecular profile, making it particularly suitable for studies of invasion, metastasis, and epithelial?Cmesenchymal transition (EMT). Derived from a human ovarian adenocarcinoma, MES-OV cells exhibit robust migratory behavior and have been characterized for their expression of cadherins and desmosomal components. Their mesenchymal features allow the dissection of desmosome-dependent adhesion in a background that already favors motile and invasive phenotypes, offering a sensitive system for detecting pro-metastatic changes upon DSC2 loss.
Desmocollin-2, encoded by DSC2, is a calcium-dependent transmembrane glycoprotein of the cadherin superfamily that forms the adhesive core of desmosomes. Within the desmosomal plaque, DSC2 interacts directly with desmogleins (such as DSG2), plakoglobin (JUP), plakophilin (PKP2), and desmoplakin (DSP) to anchor intermediate filaments, thereby maintaining tissue integrity. Its expression is regulated by upstream factors including the Wnt signaling pathway, the transcription factor p63, and protein kinase C. Downstream, DSC2 engagement influences the localization and activity of plakoglobin and desmoplakin, which in turn orchestrate cytoskeletal rearrangements and modulate Wnt/??-catenin signaling. Thus, DSC2 sits at the intersection of mechanical adhesion and signal transduction, coordinating cell?Ccell cohesion with broader transcriptional programs.
In the context of ovarian cancer, desmosomal dysfunction has been implicated in tumor progression, where loss of DSC2 may weaken intercellular adhesion, facilitating detachment, invasion, and eventual metastatic dissemination. The MES-OV DSC2 knockout polyclonal cells enable the systematic study of how desmosomal compromise affects EMT, collective cell migration, and sensitivity to chemotherapy. Because ovarian cancers often metastasize via transcoelomic spread, this model is particularly suited for investigating peritoneal dissemination and the role of adhesion molecules in anchoring tumor spheroids to the mesothelium. Moreover, the interplay between DSC2 loss and Wnt signaling can be probed to explore mechanisms of chemoresistance and tumor-initiating cell maintenance.
Key applications include western blotting to verify knockout efficiency and assess compensatory changes in other desmosomal proteins, immunofluorescence to visualize desmosome assembly and junctional integrity, and functional assays such as Boyden chamber migration, wound healing, and cell aggregation. Transcriptional profiling by RT-qPCR for EMT markers (e.g., CDH1, VIM, SNAI1) or global RNA-seq provides insights into pathway rewiring. These cells are also applicable to drug responsiveness studies evaluating agents that target Wnt signaling, protein kinase C, or cytoskeletal dynamics. For further technical details or to discuss customized experimental designs, please contact Ascent Research.
